The cholesterol controversy

被引:11
作者
Geurian, KL
机构
[1] Department of Pharmacy Practice, Univ. of Arkansas for Med. Sciences, Little Rock, AR 72205
关键词
D O I
10.1177/106002809603000512
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To provide information about the controversy associated with lowering of cholesterol concentrations to prevent coronary heart disease (CHD). DATA SOURCES: Studies, review articles, and editorials identified from MEDLINE searches (from 1966 to 1995) and bibliographies of identified articles. STUDY SELECTION: Studies, review articles, and editorials addressing controversial issues related to cholesterol lowering. DATA EXTRACTION: Pertinent information was selected and the data synthesized into a review format. DATA SYNTHESIS: Hypercholesterolemia is a well-known CHD risk factor. Reduction of serum cholesterol concentrations has been shown to reduce the incidence of CHD. Unfortunately, cholesterol lowering also appears to increase the risk for cancer, accidental and violent death, stroke, and oddly enough, CHD when certain medications are used. CONCLUSIONS: Significant reductions in serum cholesterol concentrations can be achieved with cholesterol-lowering interventions. However, the benefits associated with cholesterol reduction may not outweigh the risks in all patients with hypercholesterolemia. Cholesterol-lowering interventions should be recommended with caution in patients at increased risk for cancer, stroke, and depression. Caution should also be used when recommending fibric acid derivatives for patients with existing CHD.
引用
收藏
页码:495 / 500
页数:6
相关论文
共 60 条
  • [21] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE
    FRICK, MH
    ELO, O
    HAAPA, K
    HEINONEN, OP
    HEINSALMI, P
    HELO, P
    HUTTUNEN, JK
    KAITANIEMI, P
    KOSKINEN, P
    MANNINEN, V
    MAENPAA, H
    MALKONEN, M
    MANTTARI, M
    NOROLA, S
    PASTERNACK, A
    PIKKARAINEN, J
    ROMO, M
    SJOBLOM, T
    NIKKILA, EA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) : 1237 - 1245
  • [22] Glomset J. A., 1991, CURR OPIN LIPIDOL, V2, P118
  • [23] GOLDSTEIN MR, 1992, LANCET, V340, P127, DOI 10.1016/0140-6736(92)90461-B
  • [24] GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015
  • [25] REPORT OF THE CONFERENCE ON LOW BLOOD CHOLESTEROL - MORTALITY ASSOCIATIONS
    JACOBS, D
    BLACKBURN, H
    HIGGINS, M
    REED, D
    ISO, H
    MCMILLAN, G
    NEATON, J
    NELSON, J
    POTTER, J
    RIFKIND, B
    ROSSOUW, J
    SHEKELLE, R
    YUSUF, S
    [J]. CIRCULATION, 1992, 86 (03) : 1046 - 1060
  • [26] Joossens J V, 1988, Acta Cardiol Suppl, V29, P63
  • [27] REGRESSION OF CORONARY ATHEROSCLEROSIS DURING TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA WITH COMBINED DRUG REGIMENS
    KANE, JP
    MALLOY, MJ
    PORTS, TA
    PHILLIPS, NR
    DIEHL, JC
    HAVEL, RJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (23): : 3007 - 3012
  • [28] CHOLESTEROL IN THE PREDICTION OF ATHEROSCLEROTIC DISEASE - NEW PERSPECTIVES BASED ON THE FRAMINGHAM STUDY
    KANNEL, WB
    CASTELLI, WP
    GORDON, T
    [J]. ANNALS OF INTERNAL MEDICINE, 1979, 90 (01) : 85 - 91
  • [29] THE EFFECTS OF FAT AND CHOLESTEROL ON SOCIAL-BEHAVIOR IN MONKEYS
    KAPLAN, JR
    MANUCK, SB
    SHIVELY, C
    [J]. PSYCHOSOMATIC MEDICINE, 1991, 53 (06): : 634 - 642
  • [30] KEECH A C, 1992, European Heart Journal, V13, P162